GNN previously reported on Cuban's support for Texas radiologist Dr. Alex Oshymansky, who started a public benefit company to provide cheap pharmaceutical drugs.

The launch comes just weeks after the company's pharmacy benefit manager (PBM) operation was established; both are efforts in the pursuit to help shield consumers from inflated drug prices.

According to a September 2021 Gallup poll, 18 million Americans were recently unable to pay for at least one prescription medication for their household due to ever-rising costs, and 1 in 10 Americans have skipped doses to save money. The pharmacy's launch represents the first milestone in bringing affordable medications to millions.

Notable medications that epitomize the pharmacy's savings include Imatinib, a leukemia treatment that has a retail price of $9,657 per month but with MCCPDC costs $47 per month; Mesalamine, an aulcerative colitis treatment that retails at $940 per month comes in at $32.40 per month with MCCPDC; the gout treatment Colchicine retails at $182 month, the lowest price with a common voucher is $32 per month, and with MCCPDC it costs $8.70 per month.

Consumer-first pricing

"We will do whatever it takes to get affordable pharmaceuticals to patients," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. "The markup on potentially lifesaving drugs that people depend on is a problem that can't be ignored. It is imperative that we take action and help expand access to these medications for those who need them most."

As a registered pharmaceutical wholesaler, MCCPDC can bypass inflated markups. The pharmacy's prices reflect actual manufacturer prices plus a flat 15% margin and pharmacist fee.

Because the company refuses to pay spread prices to third-party PBM administrators in order to be allowed to process insurance claims, the online pharmacy will be a cash pay venture.